Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics of a Single Intravenous Microdose of ACD856 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 0, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics of a Single Intravenous Microdose of ACD856 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 28 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACD 856 (Primary)
  • Indications Alzheimer's disease; Sleep disorders; Traumatic brain injuries
  • Focus Pharmacokinetics
  • Sponsors AlzeCure

Most Recent Events

  • 13 Oct 2020 According to an AlzeCure Pharma AB media release, this study is a work carried out in collaboration with Professor Bengt Winblad and Professor Maria Eriksdotter at Karolinska Institutet, as well as Pontus Forsell, Johan Sandin and Gunnar Nordvall at AlzeCure.
  • 13 Oct 2020 According to an AlzeCure Pharma AB media release, the company has received a second abstract approved for poster presentation at the annual Alzheimers conference CTAD, Clinical Trials in Alzheimers Disease, which this year will be held completely digitally on 4th to 7th Nov 2020.The abstract is based on the results that led to the selection of a drug candidate (ACD856) and the recent completion of this successful clinical microdose study.
  • 13 Oct 2020 Status changed from recruiting to completed, according to an AlzeCure media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top